Treatment response to #Bulevirtide is linked to amelioration of #PortalHypertension in patients with chronic #HepatitisD

JHEP Reports
www.jhep-reports.eu/article/S258...

Loss of Bile Salt Export Pump (Bsep/Abcb11) Ameliorates Toxin-induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-terminal Kinase Signaling and Hepatic Stellate Cell Activation Loss of Bsep/Abcb11 results in a hydrophilic bile acid (BA) pool consisting of tetrahydroxylated BAs (THBAs) reducing cholestasis-induced liver injury. In this study, we investigated whether loss of B...

Loss of Bile Salt Export Pump (Bsep/Abcb11) Ameliorates Toxin-induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-terminal Kinase Signaling and Hepatic Stellate Cell Activation -

Cellular and Molecular Gastroenterology and Hepatology
www.cmghjournal.org/article/S235...

Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades Acute variceal bleeding (AVB), a severe adverse event of portal hypertension, may cause death in patients with cirrhosis. We investigated whether outcomes after AVB have improved over time.

#Liver #Cirrhosis #PortalHypertension
A recent @meduniwien.ac.at study investigated #cirrhosis pts with variceal bleeding over two 🕐 🕕 🕘 decades:
✅ decreasing rebleeding🩸rates
✅ lower bleeding-related ☠️ mortality
in the more recent decade ☺️

📕 GIE Endoscopy
🔗 www.giejournal.org/article/S001...

Pathomechanistic #Phenotypes of #Cirrhosis

Dalila Costa🇵🇹 Jonel Trebicka🇩🇪 Cristina Ripoll🇪🇸 Richard Moreau🇫🇷 @rajivjalan.bsky.social🇬🇧 Reiberger🇦🇹

📈 Portal Hypertension #PH & 🔥 Inflammation #SI coexist in pts w/ cirrhosis

💡review on PH-SI interplay in distinct cirrhosis stages
@easlnews.bsky.social

Today these two fellows rocked their VENIA DOCENDI

🎓David CHROMY : STIs & #HepatitisC
🎓Mathias JACHS : NITs in #PortalHypertension

my personal highlights:

@mathiasjachs.bsky.social in @lancetgastrohep.bsky.social
Spleen Stiffness
🔗 t.ly/DysXB

Chromy in #UEGJ
DAAs in acute #HCV
🔗 t.ly/nIZ2a

Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal

❓Does #Smoking matter in #Cirrhosis❓
@benedikthofer.bsky.social
of @meduniwien.ac.at
demonstrates that indeed smoking

📈 triggers 🔥 inflammation & 🩸angiogenesis
🦀 leads to extrahepatic cancer
🦀 and tends to increase risk of #livercancer #HCC

📕 @LiverInt
🔗 t.ly/8Vr-0

Transcriptome analysis shows that 67% (n=13563) of all human proteins (n=20162) are expressed in the liver and 978 of these genes show an elevated expression in the liver compared to other tissue types.

Source: www.proteinatlas.org/humanproteom...

Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models Scientific Reports - Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models

🚨 How do ⚡injury mechanisms and 🕑 disease states from health ➡️ fibrosis ➡️ regression shape the NO–sGC–cGMP pathway in chronic #liver #cirrhosis?

Check out our comprehensive assessment of regulation patterns of this pivotal pathway here:
rdcu.be/exM9Z

@reibergerthomas.bsky.social

🌍 #WorldHepatitisDay #2025
🇦🇹 contributions to understanding & Elimination of #Hepatitis

1⃣ #HBV-ART in #HIV 🔗 t.ly/6TXxR
2⃣ Curing #HCV in #HIV 🔗 t.ly/FiLPq
3⃣ Eliminate #HCV in 🇦🇹AT 🔗 t.ly/CBw3o
4⃣ Followup after #HCV cure 🔗 t.ly/KvSrs

Chronische #Lebererkrankungen im Fokus: @mathiasjachs.bsky.social​, #ResearcherOfTheMonth der #MedUniWien, hat gezeigt, dass Pfortaderhochdruck schmerzfrei durch Messung der Organsteifigkeit diagnostiziert werden kann.

Mehr im Video in gesamter Länge! 🎥➡️ https://bit.ly/3G6VoGC

REMEMBERING PROFESSOR JAUME BOSCH
President of Bavneo @bavenocoop.bsky.social
Friend and Mentor to many

🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation.

A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.

Rest in peace, Jaime

🎂 30Y of .mp3 🎵
created @ Frauenhofer Institute 🔗 t.ly/f6A1t
by 🧑‍🎓 Karlheinz Brandenburg 🔗 t.ly/8vojd
🙏 for good vibes when i grew up
♻️ Napster 🔗 t.ly/lqPRP
⏯️ Winamp 🔗 t.ly/_sR05

Risk of portal hypertensive complications preventable by TIPS in patients with ascites Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment of recurrent/refractory ascites in patients with cirrhosis. The aim of this study was to identify patients with ascites a...

Drs. @LorenzBALCAR of @meduniwien.ac.at & @MartaTONON identify a #cirrhosis population with #ascites at particular risk for shortterm #PortalHypertension complications

@jhepatology.bsky.social Reports: t.ly/iCvXY

Ascites #Grade3 + 🚨 MELD ≥12 or 🚨 Na ≤135
➡️ good candidates for #TIPS

Drs. @LukasHARTL and @MarleneHINTERSTEININGER of @meduniwien.ac.at showed in @CGH @AGA that
adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD

📖 the full study 🔗 t.ly/11GOg
@easlnews.bsky.social @bavenocoop.bsky.social

US News Ranking: MedUni Vienna among the best medical universities in the world Read more!

🌍⏩ #MedUniVienna ranks 66th in #ClinicalMedicine and is among the top 200 in the US News Global #UniversityRanking.

🔝📌 In the @timeshighered.bsky.social​ Impact Ranking 2025, MedUni Vienna is 10th worldwide in "Good Health and Well-Being".

Details ⬇️

The #HEPEX Hepatic Experimental Lab at @meduniwien.ac.at and @cemm.oeaw.ac.at works on Disease-driving #Pathomechanisms in #Liver #Fibrosis & #PortalHypertension

🕸️ #Macrophages in #Fibrosis Resolution
🤖 #MachineLearning & #Pathomics in #LiverHistology
🦠 #Gut-Liver-Axis
🩸 #Anticoagulation

@who.int has set Elimination of
🦠 #ViralHepatitis #B #C as a global goal for 2030

#Prisons remain a Hot ♨️ Spot for #HepC #HCV

In Vienna 🇦🇹 we focus on the incarcerated risk population
and offer onsite screening and treatment

@worldhepalliance.bsky.social
@easlnews.bsky.social

We kicked off the week with Roger Kamm (@mitdeptofbe.bsky.social) for a #CeMMinar on brain neurovascular models & its applications to modeling drug & toxin transport. Thanks to Roger for the great insights & hosts @lderooij.bsky.social & @ar-abdelfattah.bsky.social

🇦🇹 Austrian GI/Liver Meeting 2025
3 rising 🌟 stars of our research group #MOTION
@crgmotion.bsky.social @meduniwien.ac.at presented
posters on hot 🔥 topics in #Hepatology
- Clinical Course of #NAD non-acute decompensation
- #SpleenStiffness in #PortalHypertension
- #Ultrasound Elastography in MASLD

Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades Acute variceal bleeding (AVB), a severe adverse event of portal hypertension, may cause death in patients with cirrhosis. We investigated whether outcomes after AVB have improved over time.

Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades - Gastrointestinal Endoscopy www.giejournal.org/article/S001...

📈 Activation of🩸#Vasopressin System in #Cirrhosis tries to compensate for 🫀 #hemodynamic & 💧#sodium #fluid abnormalities

Drs. HARTL & HINTERSTEININGER of @meduniwien.ac.at
in 🤝with efclif.com show in📕 #CGH
🔗 t.ly/joCs5

▶️ #Vasopressin biomarker #COPEPTIN predicts #ACLF in cirrhosis

#LiverResearch team #HEPEX-Lab @meduniwien.ac.at is affiliated w Center for Molecular Medicine @cemm.oeaw.ac.at

@KatjaSommer #Gut-Liver-Axis
@VladTaru #LiverFailure #ACLF
@BenHofer #Cirrhosis #Recompensation
@KathiBonitz restaurative #Macrophages
@ThomasSorz #AI Patho Spatial Transcritomics

Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis Transjugular intrahepatic portosystemic shunt (TIPS) implantation is indicated for recurrent/refractory ascites in patients with cirrhosis. The progno…

Study by our #Liver #Team @meduniwien.ac.at
and @MedHochschuleHannover

Minimal residual ascites 3 months after #TIPS implantation implicates worse clinical outcome in patients with #liver #cirrhosis

published in @jhepatology.bsky.social #Reports

🔗 sciencedirect.com/science/arti...

#LiverSky

📘 JOURNAL OF HEPATOLOGY #JHEPATOL
@jhepatology.bsky.social

is the flagshipjournal of 🇪🇺 #EASL @easlnews.bsky.social
📈 Impact Factor of 26.8 ➡️ 2.1% 🔝Percentile

Consider to submit your #Liver #Research
🔗 www.journal-of-hepatology.eu

@heinerwedemeyer.bsky.social
@docberza.bsky.social

#LiverSky
What is shown here?

🚨 #LiverSky
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta

Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org

@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social

⚠️ #Hepatitis B Elimination
@easlnews.bsky.social @who.int @lancetgastrohep.bsky.social

😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence
😑 67% have universal #HBV birth vaccinations
☹️ Suboptimal #WHO diagnosis coverage target of 60%
😱 no country met #HBV treatment target